JanOne, Inc. focuses on developing treatments for diseases that cause severe pain. It aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The firm also provides solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. The company continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives. JanOne was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.